WHITE PLAINS, N.Y., June 10 /PRNewswire/ -- Provid Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society (LLS) today jointly announced the execution of a research agreement to advance the development of a treatment for acute myelogenous leukemia.
Under the arrangement, LLS has contracted with Provid to supply expert medicinal chemistry services in support of an LLS-funded Specialized Center of Research (SCOR) grant at the University of Virginia under the direction of Prof. John Bushweller, Ph.D.
"Provid's expertise adds a critical component to our SCOR program that will help advance our efforts from 'interesting laboratory results' to potential therapies," said Dr. Bushweller.
Louis J. DeGennaro, Ph.D., Chief Scientific Officer of LLS, added, "Our partnership with Provid is the result of a detailed selection process to identify companies that have significant drug discovery experience and fills a critical need for medicinal chemistry expertise. We believe that working with Provid will advance our research programs and speed effective therapies to our patients."
"As a company that applies medicinal chemistry expertise to transform biological discoveries into valuable drug leads, we are enthusiastic to work closely with LLS and Dr. Bushweller in the field of blood cancers," said Dr. Gary Olson, Chief Executive Officer of Provid. "We will dedicate our experienced team to this project to accelerate the validation and translation of research results from the Bushweller lab into potential leads for drug development."
The Provid partnership marks the first project of the Academic
Concierge Division announced under LLS's Therapy Acceleration Program
(TAP). This innovative program is designed to leverage current academic
research investments by providing investigators access to the same
expertise and services that pharmaceutical companies utilize. The ultimate
goal of all TAP contracts is to advance therapies for patients sufferi
|SOURCE The Leukemia & Lymphoma Society|
Copyright©2008 PR Newswire.
All rights reserved